Tenaya Therapeutics Enters into Research Collaboration with Alnylam Pharmaceuticals to Identify and Validate Novel Genetic Targets for Cardiovascular Disease Therapeutics

AI BRIEFING

• ⬤ Tenaya Therapeutics and Alnylam Pharmaceuticals collaborate to identify novel genetic targets for cardiovascular disease therapeutics.
• ⬤ Combination of Tenaya's expertise and Alnylam's ability to deliver transformational therapeutics aims to accelerate the development of new treatments.
• ⬤ Partnership will leverage Alnylam's RNA-based therapeutics platform to validate and optimize genetic targets identified by Tenaya.